Barry Buckland
Director/Board Member chez DYADIC INTERNATIONAL, INC.
Fortune : 45 381 $ au 31/03/2024
Profil
Barry C.
Buckland is the founder of Enumeral Biomedical Holdings, Inc. (founded in 2009) and Enumeral Biomedical Corp.
(founded in 2009).
He is currently the Chief Executive Officer at BioLogicB LLC since 2009, Chairman at Engineering Conferences International, Inc., Independent Director at Dyadic International, Inc. since 2018, Director at InDevR, Inc., and Advisor at Dynamk Capital LLC.
He previously held the position of Director at Synglyco, Inc., Director-Supervisory Board at Mucosis BV, Executive Director at National Institute For Innovation In Manufacturing Biopharmace, and Vice President at Merck Research Laboratories Massachusetts LLC (1980-2009).
Dr. Buckland's education includes an undergraduate degree from The University of Manchester and a doctorate from University College London (conferred in 1974).
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 03/01/2024 | 27 174 ( 0,09% ) | 45 381 $ | 31/03/2024 |
Postes actifs de Barry Buckland
| Sociétés | Poste | Début |
|---|---|---|
| DYADIC INTERNATIONAL, INC. | Director/Board Member | 03/01/2018 |
| BioLogicB LLC | Chief Executive Officer | 01/01/2009 |
Engineering Conferences International, Inc.
 Engineering Conferences International, Inc. Miscellaneous Commercial ServicesCommercial Services Engineering Conferences International, Inc. organizes engineering conferences program. The private company is based in New York. | Chairman | - |
InDevR, Inc.
 InDevR, Inc. Medical SpecialtiesHealth Technology InDevR, Inc. develops and delivers analytical tools for detection and characterization of biological molecules and microorganisms. The firm offers on the ampliPHOX Colorimetric Detection platform and Custom Arrays to enable its customers a low risk means to explore the high utility of focused microarrays. The company was founded by Kathy L. Rowlen, Laura Kuck and John W. Birks in 2003 and is headquartered in Boulder, CO. | Director/Board Member | - |
Dynamk Capital LLC
 Dynamk Capital LLC Investment ManagersFinance Dynamk Capital LLC (Dynamk Capital) is a venture capital firm founded in 2017 by Daniella Kranjac and Mario Kranjac. The firm is headquartered in New York, New York. | Consultant / Advisor | - |
Anciens postes connus de Barry Buckland
| Sociétés | Poste | Fin |
|---|---|---|
| ENUMERAL BIOMEDICAL HOLDINGS INC | Founder | 31/07/2017 |
Merck Research Laboratories Massachusetts LLC
 Merck Research Laboratories Massachusetts LLC Pharmaceuticals: MajorHealth Technology Part of Merck & Co., Inc., Merck Research Laboratories Massachusetts LLC is a pharmaceutical company that provides free medicines and adult vaccines to qualified patients through their Merck Patient Assistance Program. The private company is based in Boston, MA and is a part of Merck & Co., Inc. and its affiliates. The company also offers information about insurance coverage and financial assistance options for eligible patients. The company conducts clinical trials and provides medical information covering thousands of topics in all fields of medicine through their Merck Manuals. Additionally, they report on their commitment to operating responsibly to benefit society through their corporate responsibility program, which includes their environmental, social, and governance (ESG) report. Merck for Mothers is an initiative to create a world where no woman has to die giving life. | Corporate Officer/Principal | 01/01/2009 |
National Institute For Innovation In Manufacturing Biopharmace
 National Institute For Innovation In Manufacturing Biopharmace Miscellaneous Commercial ServicesCommercial Services The National Institute for Innovation in Manufacturing Biopharmaceuticals operates as a consortium of small, medium, and large biopharmaceutical companies. The private company is based in Newark. | Director/Board Member | - |
Mucosis BV
 Mucosis BV Miscellaneous Commercial ServicesCommercial Services Mucosis BV develops mucosal vaccines for infectious diseases. Its product is SynGEM, an intranasal vaccine to prevent respiratory syncytial virus infection. Its vaccines are based on the patented and validated Mimopath technology. This technology enables a more natural immune response as well as a broad base of protection as was seen in the proof-of-concept animal and human studies of our FluGEM vaccine candidate. The company was founded by Cornelis Leenhouts in 2007 and is headquartered in Groningen, the Netherlands. | Director/Board Member | - |
| ░░░░░░░░ ░░░░░░░░░░ ░░░░░ | ░░░░░░░ | - |
Formation de Barry Buckland
| The University of Manchester | Undergraduate Degree |
| University College London | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| DYADIC INTERNATIONAL, INC. | Health Services |
| Entreprise privées | 10 |
|---|---|
Synglyco, Inc.
 Synglyco, Inc. Pharmaceuticals: MajorHealth Technology Synglyco, Inc. develops novel vaccines using synthetic carbohydrates. The firm's cutting edge technology enables the rapid, milligram to kilogram production of synthetic carbohydrates for use in drug discovery and industrial applications. Its proprietary platform generates significant quantities of chemically pure, complex carbohydrates through automated and manual chemical synthesis. The company was founded by Peter H. Seeberger, Carmichael S. Roberts Jr. Obadiah J. Plante and Louis Schofield on June 18, 2001 and is headquartered in New York, NY. | Health Technology |
Enumeral Biomedical Holdings, Inc.
 Enumeral Biomedical Holdings, Inc. BiotechnologyHealth Technology Enumeral Biomedical Holdings, Inc. is a biopharmaceutical company, which engages in the business of discovering and developing novel antibody immunotherapies for the treatment of cancer and other diseases. It also focuses on the development of a pipeline of next generation monoclonal antibody drugs targeting established and novel immuno-modulatory receptors. The company was founded by Barry C. Buckland, John J. Rydzewski, and Arthur H. Tinkelenberg on December 11, 2009 and is headquartered in Arlington, MA. | Health Technology |
Merck Research Laboratories Massachusetts LLC
Merck Research Laboratories Massachusetts LLC Pharmaceuticals: MajorHealth Technology Part of Merck & Co., Inc., Merck Research Laboratories Massachusetts LLC is a pharmaceutical company that provides free medicines and adult vaccines to qualified patients through their Merck Patient Assistance Program. The private company is based in Boston, MA and is a part of Merck & Co., Inc. and its affiliates. The company also offers information about insurance coverage and financial assistance options for eligible patients. The company conducts clinical trials and provides medical information covering thousands of topics in all fields of medicine through their Merck Manuals. Additionally, they report on their commitment to operating responsibly to benefit society through their corporate responsibility program, which includes their environmental, social, and governance (ESG) report. Merck for Mothers is an initiative to create a world where no woman has to die giving life. | Health Technology |
Mucosis BV
Mucosis BV Miscellaneous Commercial ServicesCommercial Services Mucosis BV develops mucosal vaccines for infectious diseases. Its product is SynGEM, an intranasal vaccine to prevent respiratory syncytial virus infection. Its vaccines are based on the patented and validated Mimopath technology. This technology enables a more natural immune response as well as a broad base of protection as was seen in the proof-of-concept animal and human studies of our FluGEM vaccine candidate. The company was founded by Cornelis Leenhouts in 2007 and is headquartered in Groningen, the Netherlands. | Commercial Services |
Enumeral Biomedical Corp.
 Enumeral Biomedical Corp. Miscellaneous Commercial ServicesCommercial Services Enumeral Biomedical Corp. develops monoclonal antibodies for diagnosis and treatment of infectious, autoimmune and inflammatory diseases. Its proprietary micro engraving technology creates spatially-registered, high-density bio-chip microarrays of the secreted products of single human cells derived from patient samples to provide rapid and simultaneous analysis of antibody affinity and specificity as well as cytokine profiles and T-cell functionality. The company was founded in 2009 by J. Christopher Love, Emanuele Ostuni and Barry Buckland and is headquartered in New York, NY. | Commercial Services |
InDevR, Inc.
InDevR, Inc. Medical SpecialtiesHealth Technology InDevR, Inc. develops and delivers analytical tools for detection and characterization of biological molecules and microorganisms. The firm offers on the ampliPHOX Colorimetric Detection platform and Custom Arrays to enable its customers a low risk means to explore the high utility of focused microarrays. The company was founded by Kathy L. Rowlen, Laura Kuck and John W. Birks in 2003 and is headquartered in Boulder, CO. | Health Technology |
| BioLogicB LLC | |
Dynamk Capital LLC
Dynamk Capital LLC Investment ManagersFinance Dynamk Capital LLC (Dynamk Capital) is a venture capital firm founded in 2017 by Daniella Kranjac and Mario Kranjac. The firm is headquartered in New York, New York. | Finance |
Engineering Conferences International, Inc.
Engineering Conferences International, Inc. Miscellaneous Commercial ServicesCommercial Services Engineering Conferences International, Inc. organizes engineering conferences program. The private company is based in New York. | Commercial Services |
National Institute For Innovation In Manufacturing Biopharmace
National Institute For Innovation In Manufacturing Biopharmace Miscellaneous Commercial ServicesCommercial Services The National Institute for Innovation in Manufacturing Biopharmaceuticals operates as a consortium of small, medium, and large biopharmaceutical companies. The private company is based in Newark. | Commercial Services |
